Skip to Content
Merck
  • Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression.

Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression.

Cell reports (2020-11-19)
Jessica E Rexach, Damon Polioudakis, Anna Yin, Vivek Swarup, Timothy S Chang, Tam Nguyen, Arjun Sarkar, Lawrence Chen, Jerry Huang, Li-Chun Lin, William Seeley, John Q Trojanowski, Dheeraj Malhotra, Daniel H Geschwind
ABSTRACT

To understand how neural-immune-associated genes and pathways contribute to neurodegenerative disease pathophysiology, we performed a systematic functional genomic analysis in purified microglia and bulk tissue from mouse and human AD, FTD, and PSP. We uncover a complex temporal trajectory of microglial-immune pathways involving the type 1 interferon response associated with tau pathology in the early stages, followed by later signatures of partial immune suppression and, subsequently, the type 2 interferon response. We find that genetic risk for dementias shows disease-specific patterns of pathway enrichment. We identify drivers of two gene co-expression modules conserved from mouse to human, representing competing arms of microglial-immune activation (NAct) and suppression (NSupp) in neurodegeneration. We validate our findings by using chemogenetics, experimental perturbation data, and single-cell sequencing in post-mortem brains. Our results refine the understanding of stage- and disease-specific microglial responses, implicate microglial viral defense pathways in dementia pathophysiology, and highlight therapeutic windows.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Fatostatin hydrobromide, ≥98% (HPLC), powder